BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bruno G, Saracino A, Scudeller L, Fabrizio C, Dell'Acqua R, Milano E, Milella M, Ladisa N, Monno L, Angarano G. HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ? Int J Infect Dis 2017;62:64-71. [PMID: 28728927 DOI: 10.1016/j.ijid.2017.07.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
Number Citing Articles
1 Sikavi C, Najarian L, Saab S. Similar Sustained Virologic Response in Real-World and Clinical Trial Studies of Hepatitis C/Human Immunodeficiency Virus Coinfection. Dig Dis Sci 2018;63:2829-39. [PMID: 30094623 DOI: 10.1007/s10620-018-5215-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
2 de Gennaro N, Diella L, Monno L, Angarano G, Milella M, Saracino A. Efficacy and tolerability of DAAs in HCV-monoinfected and HCV/HIV-coinfected patients with psychiatric disorders. BMC Infect Dis 2020;20:196. [PMID: 32138757 DOI: 10.1186/s12879-020-4922-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Chalouni M, Pol S, Sogni P, Fontaine H, Lacombe K, Marc-Lacombe J, Esterle L, Dorival C, Bourlière M, Bani-Sadr F, de Ledinghen V, Zucman D, Larrey D, Salmon D, Carrat F, Wittkop L; ANRS CO13 HEPAVIH and ANRS CO22 HEPATHER cohort study groups. Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related death. J Hepatol 2021;74:37-47. [PMID: 32798585 DOI: 10.1016/j.jhep.2020.08.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
4 Falade-Nwulia O, Sutcliffe CG, Mehta SH, Moon J, Chander G, Keruly J, Katzianer J, Thomas DL, Moore RD, Sulkowski MS. Hepatitis C Elimination in People With HIV Is Contingent on Closing Gaps in the HIV Continuum. Open Forum Infect Dis 2019;6:ofz426. [PMID: 31667200 DOI: 10.1093/ofid/ofz426] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
5 Abutaleb A, Sherman KE. A changing paradigm: management and treatment of the HCV/HIV-co-infected patient. Hepatol Int 2018;12:500-9. [PMID: 30238230 DOI: 10.1007/s12072-018-9896-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
6 Sarmento-Castro R, Méndez J, Horta A, Gonçalves C, Vasconcelos O, Seabra J, Abreu M, Gonçalves MJ, Santos MJ, Tavares AP. Hepatitis C treatment outcome in former or current intravenous drug users coinfected with HIV, with or without directly observed therapy. Infect Dis (Lond) 2021;53:9-18. [PMID: 32820689 DOI: 10.1080/23744235.2020.1806352] [Reference Citation Analysis]
7 Molina-Carrión S, Brochado-Kith Ó, González-García J, Berenguer J, Díez C, Llop E, Hontañón V, Ibañez-Samaniego L, Montes ML, Resino S, Fernández-Rodríguez A, Jiménez-Sousa MÁ. Telomere Length Increase in HIV/HCV-Coinfected Patients with Cirrhosis after HCV Eradication with Direct-Acting Antivirals. J Clin Med 2020;9:E2407. [PMID: 32731419 DOI: 10.3390/jcm9082407] [Reference Citation Analysis]
8 Berenguer J, Calleja JL, Montes ML, Gil Á, Moreno A, Bañares R, Aldámiz-Echevarría T, Albillos A, Téllez MJ, Olveira A, Domínguez L, Fernández I, García-Samaniego J, Polo BA, Álvarez B, Ryan P, Barrio J, Devesa MJ, Benítez L, Santos I, Buey LG, Sanz J, Poves E, Losa JE, Fernández-Rodríguez C, Jarrín I, Calvo MJ, González-García J. HIV Coinfection Predicts Failure of Ledipasvir/Sofosbuvir in Treatment-Naïve Noncirrhotic Patients With HCV Genotype 1. Open Forum Infect Dis 2019;6:ofz214. [PMID: 31139679 DOI: 10.1093/ofid/ofz214] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
9 Mihăilă RG. Liver stiffness in chronic hepatitis C virus infection. Rom J Intern Med 2019;57:85-98. [PMID: 30447147 DOI: 10.2478/rjim-2018-0034] [Reference Citation Analysis]
10 Gonzales Zamora JA. Adverse Effects of Direct Acting Antivirals in HIV/HCV Coinfected Patients: A 4-Year Experience in Miami, Florida. Diseases 2018;6:E51. [PMID: 29921760 DOI: 10.3390/diseases6020051] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
11 Gayam V, Hossain MR, Khalid M, Chakaraborty S, Mukhtar O, Dahal S, Mandal AK, Gill A, Garlapati P, Ramakrishnaiah S, Mowyad K, Sherigar J, Mansour M, Mohanty S. Real-World Clinical Efficacy and Tolerability of Direct-Acting Antivirals in Hepatitis C Monoinfection Compared to Hepatitis C/Human Immunodeficiency Virus Coinfection in a Community Care Setting. Gut Liver 2018;12:694-703. [PMID: 29938459 DOI: 10.5009/gnl18004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
12 Lampejo T, Agarwal K, Carey I. Interferon-free direct-acting antiviral therapy for acute hepatitis C virus infection in HIV-infected individuals: A literature review. Dig Liver Dis 2018;50:113-23. [PMID: 29233687 DOI: 10.1016/j.dld.2017.11.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
13 Liu W, Jiang X, Liu Y, Ma Q. Bioinformatics Analysis of Quantitative PCR and Reverse Transcription PCR in Detecting HCV RNA. CBIO 2019;14:400-5. [DOI: 10.2174/1574893613666180703103328] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]